<DOC>
	<DOCNO>NCT02849743</DOCNO>
	<brief_summary>This research study test oxytocin , deliver nasal spray , promote weight loss child adolescent Hypothalamic Obesity compare placebo . The study divide two part . During first part , subject receive either oxytocin placebo . In second part , subject `` cross-over '' receive treatment - either oxytocin placebo . During study visit participant blood test , physical exam , metabolic testing , MRI scan , survey questionnaire .</brief_summary>
	<brief_title>Intranasal Oxytocin Hypothalamic Obesity</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Craniopharyngioma</mesh_term>
	<mesh_term>Adamantinoma</mesh_term>
	<mesh_term>Oxytocin</mesh_term>
	<criteria>1 . Proficient English . 2 . Males females age 10 21 year , inclusive . 3 . Weight ≥ 51 kg . 4 . Girls must negative urine/serum pregnancy test postmenarchal girl must use acceptable method contraception , include abstinence , barrier method ( diaphragm condom ) , DepoProvera , oral contraceptive , duration study . 5 . Hypothalamic obesity , define purpose protocol : previously diagnose brain tumor* currently obese ( BMI &gt; 95 % ile age/sex &lt; 18 year , BMI &gt; 30 kg/m2 18 21 year ) least one endocrinopathy , indicate hypothalamic damage rate annualized weight gain 6 month period ( give variability clinical course ) precede diagnosis treatment great 2 standard deviation population reference range age sex . 6 . At least 6 month since completion therapy stable disease/lack recurrence . 7 . Stable least 2 month pituitary replacement ( e.g. , glucocorticoid , thyroid hormone , estrogen/progestin testosterone , desmopressin , growth hormone ) . 8 . Stable least 2 month appetitemodulating medication ( e.g. , stimulant ) . 9 . Be able ambulate independently . 10 . Parental/guardian permission ( informed consent ) child assent . 1 . Diabetes insipidus without intact thirst mechanism ( i.e. , history participant thirsty hypernatremic and/or continue thirsty hyponatremic , participant/family and/or practitioner report medical record ) and/or `` brittle '' diabetes insipidus , define require &gt; 1 admission past year and/or admission within previous 3 month . Diabetes mellitus require insulin insulin secretagogue . Laboratory value : HgbA1c ≥8 % 2 . Cardiovascular condition , define follow : ) abnormal blood pressure , define &lt; 3 % ile &gt; 97 % ile age , sex height ; ii ) history cardiac dysrhythmia dysrhythmia detect screen EKG ; iii ) history heart failure and/or cardiomyopathy . 3 . History liver disease , screen laboratory study : Laboratory value : ALT/SGPT &gt; 3.0X upper limit normal AST/SGOT &gt; 3.0X upper limit normal 4 . History chronic kidney disease , screen laboratory study : Laboratory value : eGFR &lt; 60 mL/min/1.73m2 , define Schwartz formula 5 . Clinically significant anemia , screen laboratory study : Laboratory value : Hemoglobin &lt; 10 g/dL 6 . Seizure past 12 month . 7 . History gastrectomy , gastric bypass , small large bowel resection . 8 . History active substance abuse . 9 . Current psychotic disorder and/or suicidality . 10 . Supraphysiologic ( &gt; 15 mg/m2/day ) prescribe dos hydrocortisone equivalent . 11 . Anticipated clinical plan initiate modify pituitary hormone replacement and/or appetitemodulating drug course study . 12 . Any investigational drug use within 30 day prior enrollment . 13 . Pregnant lactating female . 14 . Individuals know sensitivity either oxytocin component formulation . 15 . Inability take intranasal medication ( e.g. , recent injury ) . 16 . Parents/guardians subject , opinion Investigator , may noncompliant study schedule procedure .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>oxytocin</keyword>
	<keyword>hypothalamic obesity</keyword>
	<keyword>craniopharyngioma</keyword>
	<keyword>metabolism</keyword>
</DOC>